Ibrutinib’s Cardiotoxicity—An Opportunity for Postmarketing Regulation

Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) that is indicated for multiple haematological malignancies. This Viewpoint discusses its cardiotoxicity and the need for further research and post-marketing regulation.

Source:

JAMA Oncology